Key result
Octreotide treatment in CF-LVAD patients with recurrent GI bleeding showed no overall difference, but a trend toward reduced hospitalizations and transfusions when excluding one patient (p=0.06).
Why the study?
Does octreotide reduce hospitalizations due to GI bleeding, blood transfusions, and endoscopic procedures in CF-LVAD patients with recurrent GI bleeding?
Observational (n=7)
No
Does octreotide reduce hospitalizations due to GI bleeding, blood transfusions, and endoscopic procedures in CF-LVAD patients with recurrent GI bleeding?
p-value: p=0.06
Off-label use of chronic octreotide injections showed a favorable trend in reducing hospitalizations and transfusions for recurrent GI bleeding in CF-LVAD patients when excluding one outlier.
Should not yet change practice for octreotide in CF-LVAD GI bleeding; leaves open efficacy pending randomized trials.
Gastrointestinal (GI) bleeding is the most common cause of readmission in patients supported by continuous flow left ventricular assist devices (CF-LVAD). We describe our experience in the off-label use of octreotide in the management of recurrent GI bleed in this population. Of 116 patients implanted with a CF-LVAD at our institution, seven had recurrent GI bleeding unresponsive to conventional management and were started in chronic octreotide injections. Hospitalizations due to GI bleeding, number of packed red blood cells transfused, and number of endoscopic procedures were compared 3 months before and after octreotide treatment. In the overall cohort, there were no differences in these three endpoints. When one patient with differing characteristics was excluded from the analysis there was a trend (p = 0.06) to a reduction of hospitalizations due to GI bleeding, number of blood transfusions, and number of endoscopic procedures. Octreotide exhibit a favorable trend in the frequency of admissions, blood transfusions, and endoscopic procedures in most patients with recurrent GI bleed. Further prospective studies are needed to clarify its benefits in this population.
No takes yet. Share an insight, caveat, or question.
Loyaga‐Rendon et al. (2014) conducted an observational in Recurrent gastrointestinal bleeding in patients with continuous flow left ventricular assist devices (n=7). Octreotide vs. 3 months before treatment was evaluated on Hospitalizations due to GI bleeding, number of packed red blood cells transfused, and number of endoscopic procedures (p=0.06). Octreotide treatment in CF-LVAD patients with recurrent GI bleeding showed no overall difference, but a trend toward reduced hospitalizations and transfusions when excluding one patient (p=0.06).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: